An immunomodulatory peptide derived from the thymus gland, approved in several countries for hepatitis B/C and studied for immune enhancement in cancer and infectious diseases.
Future oncology (London, England)|2021|Bersanelli M et al.|8 citations
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized s…
Review
PMID: 33538178
International journal of molecular sciences|2021|Ghigo A et al.|27 citations
Cystic fibrosis (CF) is an inherited disorder caused by mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an ATP-gated chloride channel expressed on the apical surface of airway epithelial cell…
Review
PMID: 33669352
Materials (Basel, Switzerland)|2021|Aslam M et al.|4 citations
Human interferon α2 (IFNα2) and thymosin α1 (Tα1) are therapeutic proteins used for the treatment of viral infections and different types of cancer. Both IFNα2 and Tα1 show a synergic effect in their activities when used in combination. Furthermore,…
In Vitro
PMID: 34203928
Frontiers in medicine|2021|Huang C et al.|13 citations
Thymosin alpha 1 (Thymosin-α1) is a potential treatment for patients with COVID-19. We aimed to determine the effect of Thymosin-α1 in non-severe patients with COVID-19.We retrospectively enrolled 1,388 non-severe patients with COVID-19. The primary…
PMID: 33968969
Medicine|2021|Linye H et al.|6 citations
Thymosin alpha-1 (Tα1) is an immunomodulatory and antiviral agent with potential effects on chronic hepatitis B and liver cancer. Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of…
PMID: 34011034
International immunopharmacology|2021|Chen M et al.|10 citations
BACKGROUND: Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive and poor prognostic malignant tumor along with high-level infection of Epstein-Barr virus (EBV). Gemcitabine (Gem) and Thymosin alpha 1 (Tα1) exert an anti-tumor effect in vari…
Animal StudyIn Vitro
PMID: 34119916
Journal of ethnopharmacology|2021|Chen L et al.|6 citations
ETHNOPHARMACOLOGICAL RELEVANCE: Kidney-yin deficiency (KYD) during pregnancy is common and associated with possibility of thymus hypoplasia in neonates. Zuogui Wan (ZGW) is a classic traditional medicine to treat KYD. AIM OF STUDY: The Wnt/β-catenin…
Animal StudyIn Vitro
PMID: 34146629
Frontiers in immunology|2021|Wang Z et al.|13 citations
Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Tα1) is used in the management of COVID-19, because it is known to restore the homeostasis of the immune system during infections and cancers. We aim to observe the…
PMID: 34149679
European review for medical and pharmacological sciences|2021|Gaziano R et al.|9 citations
Currently, the COVID-19 pandemic, caused by the novel SARS-CoV-2 coronavirus, represents the greatest global health threat. Most people infected by the virus present mild to moderate respiratory symptoms and recover with supportive treatments. Howeve…
Review
PMID: 34156699
Translational oncology|2021|Shi D et al.|8 citations
Breast cancer is currently one of the most common malignant tumors in women. Our previous research found that thymic dysfunction has a certain relationship with the occurrence and development of breast cancer. In order to explore whether the function…
Animal Study
PMID: 33395746
Medicine|2021|Huang W et al.|1 citation
INTRODUCTION: Patients with coronavirus disease (COVID-19) may develop acute respiratory distress syndrome (ARDS). There have been few reports of postpartum woman with ARDS secondary to COVID-19 who required respiratory support using veno-venous extr…
Case Report
PMID: 34397736
Frontiers in immunology|2021|Liu J et al.|14 citations
BACKGROUND: Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear. This study aimed to explore the efficacy of Tα1 as a COVID-19 therapy. METHODS: We performed a multicenter cohort study…
PMID: 34408744
Journal of the American Chemical Society|2021|Distler M et al.|40 citations
Herein, a method for synthesizing and utilizing DNA dendrons to deliver biomolecules to living cells is reported. Inspired by high-density nucleic acid nanostructures, such as spherical nucleic acids, we hypothesized that small clusters of nucleic ac…
PMID: 34410116
ACS omega|2021|Chen Q et al.|5 citations
Targeted drug delivery into cells has been of tremendous scientific interest, and carbon nanotubes (CNTs) can be deemed as a promising material for the loading and unloading of drugs. One of the major challenges is the release of drugs from CNTs, whi…
PMID: 34693169
Chinese medical journal|2021|Guo C et al.|19 citations
BACKGROUND: There is limited information about thymosin α1 (Tα1) as adjuvant immunomodulatory therapy, either used alone or combined with other treatments, in patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the effect o…
PMID: 34732663
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie|2020|Yang Z et al.|12 citations
BACKGROUND: Thymosin alpha-1 (TA) has been reported to inhibit tumor growth as an immunomodulator. However, its mechanism of action in immunosuppressive cells is unclear. The purpose of this study was to investigate whether TA can reshape the immune…
Animal Study
PMID: 32942159
BMJ open|2020|Zhou J et al.|10 citations
INTRODUCTION: Infected pancreatic necrosis (IPN) and its related septic complications are the major causes of death in patients with acute necrotising pancreatitis (ANP). Therefore, the prevention of IPN is of great clinical value, and immunomodulato…
PMID: 32994239
BMC gastroenterology|2020|Peng D et al.|4 citations
BACKGROUND: Previous studies have demonstrated the benefits of thymosin alpha-1 (Tα1) in anti-virus, immunological enhancement and anti-inflammation. However, it is controversial about the efficacy and safety of entecavir (ETV) plus Tα1 combination t…
ReviewMeta-Analysis
PMID: 33076834
Vaccines|2020|Costantini C, van de Veerdonk F, Romani L|25 citations
The immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a critical factor in the clinical presentation of COVID-19, which may range from asymptomatic to a fatal, multi-organ disease. A dysregulated immune response not o…
Review
PMID: 33271780
Clinical laboratory|2020|Yang Z et al.|3 citations
BACKGROUND: Coronavirus disease (COVID-19) has affected more than 100 countries worldwide and the discharge criteria of patients with COVID-19 vary across different countries. In China, patients with two negative respiratory viral RNA tests taken at…
Case Report
PMID: 33337843